Welcome to OcuFLOW™
“Alterations in ocular blood flow have been implicated in mechanisms that lead to vision loss in patients with various ocular disorders such as diabetic retinopathy, glaucoma, and age-related macular degeneration. Assessment of retinal and choroidal blood flow is also a window to evaluate systemic diseases that affect microvasculature. Quantification and qualification of the blood flow in the retina and choroid help us understand pathophysiology, stratify disease risk, and monitor disease progression in these disorders.”
(*Wei et al, 2018)
OcuFLOW, Inc. is dedicated to the development of ocular device technology that provides early, clinically significant data on ocular blood blow to assist in managing blindness-causing conditions. Our product is a pre-market composite pulsatile ocular blood flow analyzer (COBFA) that supports a solution to managing ocular blood flow.
According to the National Eye Institute, in 2014 an estimated 12.5 million Americans had one of the three most common blinding conditions: age-related macular degeneration, diabetic eye disease, and glaucoma. This will double to 26.3 million by 2050. A protocol that includes measurement and management of ocular blood flow may provide early, non-invasive treatment options to delay the progression of these blinding-eye conditions. No other device on the market measures ocular blood flow.
Based in Maryland, OcuFLOWTM strives to transform lives, applying technological innovation to impact treatments that delay the progression of devastating eye disease.
* Wei X, Balne PB, Meissner K, Barathi VA, Schmetterer L, Agrawal R. Assessment of flow dynamics in retinal and choroidal microcirculation. Survey of Ophthalmology 2018: 1-19
The OcuFLOW Composite Ocular Blood Flow Analyzer is a premarket medical device and has not been cleared by the FDA. The information contained herein is for investor and scientific investigational research use only.